Jasper Therapeutics, Inc.
JSPR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.21 | 0.03 | 0.01 | -0.01 |
| FCF Yield | -20.25% | -63.54% | -263.53% | -40.38% |
| EV / EBITDA | -3.39 | 0.03 | 0.34 | -0.21 |
| Quality | ||||
| ROIC | -115.80% | -80.45% | -118.99% | -40.99% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.88 | 0.81 | 1.22 | 1.10 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -20.67% | -12.71% | -28.60% | -97.66% |
| Safety | ||||
| Net Debt / EBITDA | 0.98 | 1.29 | 0.69 | 2.24 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1,070.54 | -1,366.77 | -492.61 | -2,527.27 |